U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT06959979) titled 'Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma' on July 24, 2024.
Brief Summary: Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a ...